EMVCAPITAL PLC

DEEP TECH | LIFE SCIENCES | SUSTAINABILITY

Virtual Meet the Portfolio

Dname-iT Holdings
Vortex Biotech Holdings

26 February 2026

DISCLAIMER

This presentation (and any information contained in any oral presentation accompanying it) (**Presentation**) has been prepared by EMV Capital plc (**Company**). This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (**FSMA**). This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Any person who receives this Presentation should not rely or act upon it. Any person who is in any doubt about this Presentation should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

Whilst the information contained in this Presentation has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as **Information**) and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation. All statements of opinion and/or belief contained in this Presentation and all views expressed represent the directors' own current assessment and interpretation of information available to them as at the date of this Presentation.

This Presentation has not been fully or independently verified and is subject to material updating, revision and further amendment. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

This Presentation contains certain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements include, but are not limited to, statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, forecasts, projections, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Therefore, actual results and future events could differ materially from those anticipated in such statements. No representation is made or assurance given that such statements or views are correct or that the objectives of the Company will be achieved. The reader is cautioned not to place reliance on these statements or views and no responsibility is accepted by the Company or any of its shareholders, directors, officers, agents, employees or advisers in respect thereof.

This Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.

Neither this Presentation nor any copy of it may be: (a) taken or transmitted into Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a **Restricted Territory**), their territories or possessions; (b) distributed to any US person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)); or (c) distributed to any individual outside a Restricted Territory who is a resident thereof, in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

By accepting receipt or attending any delivery of, or electronically accessing, this Presentation, each recipient agrees to be bound by the above limitations and conditions and, in particular represents, warrants and undertakes to the Company that: (i) they will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose; and (ii) they agree to comply with the contents of this notice.

INTRODUCTION TO EMV CAPITAL PLC

Vision to be a **leading VC investment group** in the deep tech and life sciences sectors

Started from £12m AUM and 8 companies in 2020

Identifying, investing in, and building **high growth companies** in the UK and internationally

£104m+ Assets Under Management (AUM) at 30 June 2025

- £38.6m in direct balance sheet holdings
- £66.1m in managed and third-party holdings

70 portfolio companies

Building a sustainable platform to reach next milestone of **£200m+ AUM**

EMV Capital Partners Limited

FCA authorised fundraising and fund management practices

OPERATING MODEL: CAPITAL GROWTH

GROW VALUE OF OUR PORTFOLIO COMPANIES



VENTURE BUILDING

Selective capital efficient balance sheet investment and in-kind services to capitalise upon value opportunities

CORPORATE FINANCE

Facilitating and syndicating external funding for portfolio companies to execute growth and development

PROACTIVE MANAGEMENT

Proactive engagement with company Boards and co-investors – protecting value and driving for returns

VALUE CREATION SERVICES

Supporting a cohort of companies in protecting value and value growth

Support includes investment and exit readiness, business and financial strategy, leadership buildout, corporate collaborations

ROUTES TO EXIT

Proactive drive towards profitable cash exits (partial or full)

To deliver capital gains and carried interest from exits

EMV CAPITAL PORTFOLIO

DEEP TECH & LIFE SCIENCES – SELECTED COMPANIES

DEEP TECH PORTFOLIO

FUTURE OF COMPUTE

ALLFOCAL OPTICS · NU QUANTUM · POROTECH

SEMICONDUCTORS

PARAGRAF · CGD CAMBRIDGE GaN DEVICES

SENSING

PointGrab · converge · FocalPoint · SPOTTA · PervasID · SOREXSENSORS · Plumis

AI, AUTONOMOUS SYSTEMS & ROBOTICS

q-bot · Techspert · ROBOK · Signaloid · OctaiPipe · Dogtooth · Myrtle.ai

NOVEL MATERIALS

DeepTech Recycling · ventive · Echion Technologies · Xampla · radiant matter. · PX PLASTOMETREX

SPACETECH AND SATCOMMS

sofant technologies · OXFORD SPACE SYSTEMS

LIFE SCIENCES PORTFOLIO

DRUG DISCOVERY & THERAPEUTICS

AIVIVO · PHARMENABLE · AMR Bio · PDS Biotechnology · INFINITOPES · Exonate

MEDTECH & DIAGNOSTICS

Cytovale · ProAxsis · Camstent · NoBACZ Healthcare · Kalium Health™ · Vortex · Glycotest · Cambridge Nutraceuticals

DIGITAL HEALTH

WandaHealth · Patient Source · ieso · strolll · Closed Loop Medicine · psyomics™

TOOLS & TECHNOLOGIES

EPIBONE · DName-iT · AXOL · PENCIL Biosciences · semarion · SAGETECH MEDICAL · NunaBio · Qkine

EMVC VENTURE BUILD PROGRAMME:
DRIVING VALUE AND SHAREHOLDER RETURNS

Approach

- Target IP-rich companies needing strategic direction
- Working within large/growing markets
- Restructure via direct equity (cash and/or in-kind services)
- Deploy EMV Capital shares where appropriate

Growth Support

- Syndicated third-party capital
- Value creation services (commercial, operational, exit-readiness)
- Help companies 'graduate' to access growth capital

DName-iT

Lab Blood Verification System

FV stake increase of £1.7m

25.9% direct, 30.2% advised

Vortex BIOSCIENCES

Liquid biopsy / cancer diagnostics

FV stake increase of £2.8m

22.1% direct, 13.9% advised

Capital efficient model with strong embedded upside

DName-iT

improving safety, quality and cost in patient testing

Investor Summary | February 2026

DName-iT provides molecular level assurance and cost reduction in next generation DNA sequencing for medical testing

- Modern medical DNA testing widely involves the use of Next Generation Sequencing (NGS)
- Major uses include oncology testing, pre-natal screening and inherited disease identification
- NGS operates at scale to increase efficiency
- However, **scale and high throughput introduces risk**, including including handling, sample and reagent contamination, leading to mis-identification of patient specimens and inaccurate test results
- Current mitigations for these risks are mainly procedural (tube labelling, written protocols, test duplication etc) and are expensive while still risking errors
- Mistakes increase costs for laboratories, create compliance issues and reduce confidence for payers, clinicians and patients. Test errors can have serious consequences for patient care and clinician liability
- DName-iT produces proprietary DNA-based patient-specific 'barcodes' which provide assurance at the molecular level

Next Generation Sequencing steps

DName-iT has a simple and compelling value proposition

Tube manufacturers

Transforms sample tubes from a commodity consumable into a differentiated quality enabling system, enabling **premium pricing**

Laboratories

Increases **quality and safety** and **reduces costs** from repeat tests without disrupting existing workflows

Healthcare systems & payers

Reduces costs and enhances **public confidence** and **traceability**

Patients

Improved **safety, confidence** and **speed** to results

The global NGS market is growing rapidly

CAGR 15-20%

Current market $10-11billion

Oncology accounts for one third of all applications

3 million NIPT tests are carried out each year in EU and US

As NGS testing scales in volume, complexity and is decentralised; sample identity becomes as critical as analytical sensitivity.



- Oncology and Non-Invasive Pre-natal Testing (NIPT) account for over 50% of all NGS use. Genetic and infectious disease screening makes up the vast majority of the rest.
- The DName-iT system is currently applicable to over 95% of all oncology methods (liquid biopsy) – this segment is the fastest growing.
- US and EU account for 75% of the liquid biopsy market. Assuming a market penetration of 15% of NGS-based tests this would equate to around 0.6 million tests per year
- 65% of NIPT methods are amenable to DName-iT methods. Assuming a market penetration of 15% of NGS-based tests this would equate to around 0.5 million tests per year

Sources: 2021 BioConAct NGS Market Analysis Report; Grand View Research, Liquid Biopsy Market (2025 - 2030)

DName-iT's IP assets enable two routes to revenue

DName-iT maintains a comprehensive patent portfolio with broad claims covering the company's proprietary products and methods.



1 productisation

DName-iT has the opportunity to commercialise a differentiated assurance and identity solution for NGS testing.

This represents a long-term revenue opportunity in a global growth market.

2 patent licensing

Our analysis suggests DName-iT patented methodology is being widely used by NGS companies in violation of DName-iT's rights.

A significant historic commercial license provides precedent.

A partner is required to fund litigation.

Productisation: go to market strategy and execution plan

Progress to date:

- ✓ DNames™ manufacture proven
- ✓ Regulatory framework in place
- ✓ Comprehensive patent position
- ✓ Analytical software developed

molecular and digital layer
(DName-iT control data and IP)

- Certified labs produce barcodes
- DName-iT software and sequence lists
- DName-iT specified solutions

physical manufacturing layer
(tube maker control quality of hardware and brand)

- Sample tubes manufactured in partnership
- Integrated product manufactured under partner brand

- Blood collection tubes containing DNames™ barcodes
- Enriching solution
- List of DNames™ unique sequences
- Analysis software
- License to relevant patents and written protocols

product bundle

- Product packaged as a DName-iT-enabled sample tube system
- Sold to testing laboratories by sample tube manufacturer
- Co-marketing agreement

Revenue model

- Laboratory purchases from sample tube manufacturer
- Revenue split between DName-iT and sample tube manufacturer

2026 plan

The critical steps in 2026 are to complete a commercial pilot and select a tube manufacturing partner

Q1
- Design pilot
- Complete regulatory work
- Identify pilot partner

Q2
- Contract pilot partner
- Manufacture pilot tubes

Q3
- Pilot execution & evaluation
- Identify commercialisation partners

Q4
- LOI / MOU with commercialisation parter

Patent Licensing: partnering to enforce DName-iT's rights and monetise IP

- We believe (and have compelling analysis to support) that many of the multinational NGS companies are currently using methods covered by DName-iT's patents
- Royalty rates could be in the range 2 – 5% of relevant company revenue, which puts the total prize in excess of **$150m**
- One single target licensee could generate **$40m per annnum** alone at 2% royalty rates
- DName-iT is currently negotiating with patent funding specialists
- Initial due diligence has been successfully concluded, and we expect a transaction term sheet within the next month

DName-iT

- Deep and unique technical knowledge
- Continued IP development
- Exhaustive and documented competitor patent and methods analysis

+

Litigation partner

- Track record of delivering value from IP
- Global reach & resources
- Specialist expertise in patent assertion

The DName-iT Team

Founded in late 2014 by renowned Prof. Harry Cuppens, DName-iT was spun-out from KU Leuven University, now backed by EMV Capital and has a strong team combining both world-class technical expertise and licensing experience

Prof Harry Cuppens, CSO and Founder

Following research and Professorial roles at KU Leuven, founded DName-iT. Deep industry and technical experience in genetics, biotechnology, genetic testing technologies, development of DNA and RNA technologies, next-generation sequencing, cystic fibrosis.

Dr Stephen Cook, CEO

25 years experience in energy industry, working for BP plc. Led BP's IP monetization and licensing business. Led BP's scale-up and corporate venture capital group. Currently advising investment funds and has NED and Chair roles in deep-tech start-ups.

Silanur Sahin, CCO

Cambridge MBA with cross-functional experience in med-tech operations and law. Specializing in scalable growth and regulatory-backed commercialization strategy. Experience in medical sample tube manufacturing.

Dr Ilian Iliev, Board Chair

CEO of EMV Capital plc, highly experienced investor with a track record of delivering investor returns on IP-rich companies

Kevin Dean, NED

40 years experience in new technology, including 20+ years in Digital Health & MedTech. Past roles include as Healthcare innovation lead for Cisco; Interim Director General, IT, NHS; NED Genomics England; Chair of three MedTech start-ups; worked with VC / Investment companies in Europe including EMV Capital, Industrifonden and Nordic Ninja VC.

Stephen Crowe, fractional CFO

CFO of EMV Capital plc, a commercial, growth focused and highly experienced finance leader with over 20 years in a wide range of financial institutions.

Vortex

Investor Summary

CTC-Centred Service Solution for Biopharma

H1 2026 | Confidential

The Problem
90% of cancer deaths are caused by metastasis

Circulating Tumour Cells (CTCs) are a primary driver of metastasis
Early and ongoing detection of CTCs is key to successful treatment

Cancer is a Major Global Challenge

- 2022: 20M new cases, 9.7M deaths
- 2040 projection: 29.5M cases, 16.4M deaths
- CTCs are primary drivers of metastasis
- Increasingly powerful and personalized drugs - but early detection *and* monitoring during treatment critical for survival

Current Solutions Fall Short

- ctDNA: Limited to DNA fragments, no cellular context
- Tissue biopsy: Invasive, costly ($15k-$45k)
- Historic CTC tech: Damages cells, low purity

Market gap for detection of intact, viable CTCs

THE VORTEX SOLUTION

CTC-centred solution for biopharma clients developing personalised cancer therapies

Vortex technology platform isolates **intact, label-free and pure CTCs** from whole blood.

Vortex's core technology platform consists of:

- Patented VTX-1 Platform – a **fully automated, "no-touch" CTC isolation instrument**
- **Reagent-free cartridge** (containing an onboard micro-fluidic chip)

Efficiency:

- 60-70% cell recovery rate
- Intact cells
- Variety of cancer types

Usability:

- <2 hours processing/run time
- Fully-automated and user-friendly
- Flexible output giving a wide range of options for downstream analysis

Purity:

- <100 White Blood Cells per mL of blood
- Label free
- Unaltered cells

Market Opportunity:
CTC-based liquid biopsy is now set to grow

Global Market Growth ($ Bn)



Market Drivers

- **Accelerated Market Growth:**
  - Liquid biopsy market is scaling rapidly
  - Expanding multi-billion-dollar addressable markets
- **Technology-Driven Market Expansion:**
  - Shift to High-Value, Minimally Invasive Diagnostics
  - Advances in NGS, ctDNA analytics
  - AI-powered interpretation
  - Dramatically increasing test accuracy and clinical utility
- Move to premium-priced products, broader indications
- Faster penetration into oncology and therapy selection

Sources: 1 Grand View Research: Liquid Biopsy Market Size & Share, Industry Report, 2030
Sources: 2 Global Market Statistics: Circulating Tumor Cells Market

Investment Highlights

Strategic Partnerships

TDL/Sonic Healthcare partnership & global CRO access
AstraZeneca Exchange
Axon DX (US) technology partnership
Cambridge x Manchester Innovation Partnership

International Clinical Network

UK: NHS, UCL, Manchester University
USA: University of Maryland Medical Centre
EU: Medical University Vienna, CHU Nice

Clinical Validation

3 ongoing clinical studies (200+ patients), results expected in 2026

Capital-light Manufacturing

Cost-optimized production, on-demand build capability for platform (UK)
Proven scaled cartridge production (Germany, South Korea)

IP Protection

12 granted/pending patents;
Exclusive UCLA/Harvard licenses
Design and trade secrets

Clear Path to Revenue

Service lab operational;
Pharma contracts advancing
Previously small-scale revenues from unit rental and cartridge sales

Use Case: Culturing CTCs for Drug Development

Unlocking the Holy Grail of Precision Medicine: Living CTC Cultures for Real-World Drug Development

Challenges: CTCs are extremely rare, difficult to expand, and long-term culture often causes phenotypic/genotypic drift that reduces their clinical relevance.

Vortex Solution: Vortex is uniquely gentle on CTCs, non-contact isolation preserves viability unlike competitor methods

Benefits: When successful, cultured CTCs provide renewable, patient-specific tumour models that enable individualized drug susceptibility testing and mechanistic discovery.

Drug discovery value: CTC-derived cultures capture highly metastatic, therapy resistant tumour subclones, offering unique platforms to screen drugs and identify effective combination strategies.



"Cultured CTCs provide functional models for drug susceptibility testing, enabling evaluation of therapeutic responses using patient-specific tumor cells"

Prof. Claire Hur, Johns Hopkins University, USA

Clinical Validation:
Multiple clinical validation studies planned/under way

University of Maryland

Lead: Prof. Stuart Martin
50 patients: Breast & Lung Cancer
Expanded trial, reporting Q1 2026

Medical Univ. Vienna

Lead: Prof. Robert Zeillinger
200 patients: Ovarian Cancer
Multi-year follow-up ongoing

CHU Nice, France

Lead: Prof. Paul Hofmann
50 patients: Uveal Melanoma
Completed, reporting 2026

Studies on multiple cancer types reporting out throughout 2026, with follow-on studies planned

Go to Market Strategy

Near term revenue opportunities from University placements…
…Building up to clinical trial contracts

Research Institutions

- VTX-1 instrument placement
- £130k per unit / £4k monthly rent
- Recurring cartridge sales (1,000s units)
- Target: KOL labs & Research Centres
- Data analytics opportunity from CTC databank

Pharma, CROs, Path Labs

- Vortex service lab (Manchester, UK)
- Biomarker assay development: £200k-£500k
- Clinical trials (P1-P3): £1,025/sample
- Expected revenue: £800k-£1.2M per P1 trial
- Workflow deployable in partner labs

Strategic Partnerships

TDL / Sonic Healthcare

Global Laboratory Partner

VTX-1 installed at TDL (London); Access to global Sonic network

AstraZeneca

Pharma Development

Technology assessment 2026; AZ Exchange program participant

Manchester Knowledge Quarter

NHS & Academic Access

10 hospitals, 3M patient data, 40k health/life science students

Vortex is engaged with partners to gather evidence, integrate downstream applications, and build a customer base

Commercial Pipeline

Advanced discussions with leading pharma and CROs

Leading UK/EU Pathology Lab

Pilot Q1 2026, VTX-1 installed

Global Healthcare Consulting Firm

Clinical expert network engagement

Multiple Pharma Companies

R&D integration discussions

THE DOCTORS LABORATORY

Strategic Global Partnership with TDL, Sonic Healthcare, UCL

Vortex workflow installed in The Doctors Laboratory facilities. (Halo Building, London)

Workflow validation and strong potential for expanded market reach into contracts with CRO's and Big Pharma

The Doctors Laboratory (TDL) is a key part of Sonic Healthcare, one of the world's largest clinical diagnostics groups with extensive operations across Europe, North America, and Australasia. TDL sits within a multinational network of over 1,400 specialist pathologists and advanced laboratories, enabling it to deliver high-volume, high-complexity diagnostics at scale

Commercial Roadmap

Q1 2026	TDL/Sonic partnership; Manchester labs opened, first clinical study results
Q2 2026	VTX-1.5 production scale-up; Cost optimization
Q3 2026	Additional study readouts, AstraZeneca Tech assessment
Q4 2026	Pharma/CRO pilot initiations; Validated VTX-1.5
2027+	Scale service delivery; Series A positioning, Strategic exit discussions

Exit Strategy

Active M&A market with strategic acquirers across multiple categories

- CTC Technology Companies
- ctDNA Liquid Biopsy Players
- Laboratory Service Providers
- Pharmaceutical Companies
- Single Cell Specialists
- Medical Instrument Manufacturers
- CRO Companies

Recent Transactions: $390M-$23B (Exact Sciences/Thrive, Illumina/Grail, NeoGenomics, ArcherDX)

Leadership Team

Nigel Brooksby

Non-Executive Chairman

Former Chairman/CEO Sanofi UK. Senior roles: Sanofi, GSK, Pfizer. Deep global pharma network

Paul Reeves

Managing Director

20+ years diagnostics/MedTech. Led R&D at VetPlus, Arcis, QIAGEN (Therascreen® FDA approval). PhD + MBA.

Dr Ilian Iliev

Investment Director

CEO EMV Capital PLC. Experience in high-growth tech, IP strategy, diagnostics, institutional investors.

Jacqueline Hall

VP, Offering Development

20+ years in genomics/clinical research, Deep expertise in using data to improve patient outcomes

Kevin Dean

Strategy Advisor

30+ years in healthcare. Former Innovation Director, Cisco. Former NED, Genomics England, Senior Fellow, RAND Europe.

John Matthews

VP, Clinical Operations

30 years in pharmaceutical/CRO sector. Led large global, inspection-ready clinical trials

Liquid biopsies are leading us into a new era of personalised cancer care

Professor Peter Johnson CBE

NHS National Clinical Director for Cancer, June 2025

EMV CAPITAL PLC



JOIN OUR COMMUNITY

Follow EMV Capital plc on LinkedIn & Twitter

25-28 Old Burlington Street, London W1S 3AN
www.emvcapital.com